Terms: = Liver cancer AND EML4, ENSG00000143924, 27436
25 results:
1. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
Wu S; Liu Y; Shi X; Zhou W; Zeng X
Dig Liver Dis; 2023 Dec; 55(12):1757-1764. PubMed ID: 37142453
[TBL] [Abstract] [Full Text] [Related]
2. Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.
Shiraishi T; Yamasaki K; Kidogawa M; Shingu T; Ujimiya F; Jotatsu T; Matsumoto S; Izumi H; Nishida C; Goto K; Yatera K
Intern Med; 2023 Nov; 62(21):3215-3221. PubMed ID: 36927974
[TBL] [Abstract] [Full Text] [Related]
3. Multisystem ALK-positive histiocytosis: a multi-case study and literature review.
Liu W; Liu HJ; Wang WY; Tang Y; Zhao S; Zhang WY; Yan JQ; Liu WP
Orphanet J Rare Dis; 2023 Mar; 18(1):53. PubMed ID: 36915094
[TBL] [Abstract] [Full Text] [Related]
4. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
Zhang Y; Fang H; Hong J; Wang X; Wang H; Pan G
Medicine (Baltimore); 2022 Aug; 101(33):e30094. PubMed ID: 35984185
[TBL] [Abstract] [Full Text] [Related]
5. Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China.
Su C; Zhou J; Qiang H; Zhao J; Chang Q; Ji X; Li J; Xie M; Chu T
Int J Cancer; 2023 Jan; 152(1):15-23. PubMed ID: 35579989
[TBL] [Abstract] [Full Text] [Related]
6. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.
Kemps PG; Picarsic J; Durham BH; Hélias-Rodzewicz Z; Hiemcke-Jiwa L; van den Bos C; van de Wetering MD; van Noesel CJM; van Laar JAM; Verdijk RM; Flucke UE; Hogendoorn PCW; Woei-A-Jin FJSH; Sciot R; Beilken A; Feuerhake F; Ebinger M; Möhle R; Fend F; Bornemann A; Wiegering V; Ernestus K; Méry T; Gryniewicz-Kwiatkowska O; Dembowska-Baginska B; Evseev DA; Potapenko V; Baykov VV; Gaspari S; Rossi S; Gessi M; Tamburrini G; Héritier S; Donadieu J; Bonneau-Lagacherie J; Lamaison C; Farnault L; Fraitag S; Jullié ML; Haroche J; Collin M; Allotey J; Madni M; Turner K; Picton S; Barbaro PM; Poulin A; Tam IS; El Demellawy D; Empringham B; Whitlock JA; Raghunathan A; Swanson AA; Suchi M; Brandt JM; Yaseen NR; Weinstein JL; Eldem I; Sisk BA; Sridhar V; Atkinson M; Massoth LR; Hornick JL; Alexandrescu S; Yeo KK; Petrova-Drus K; Peeke SZ; Muñoz-Arcos LS; Leino DG; Grier DD; Lorsbach R; Roy S; Kumar AR; Garg S; Tiwari N; Schafernak KT; Henry MM; van Halteren AGS; Abla O; Diamond EL; Emile JF
Blood; 2022 Jan; 139(2):256-280. PubMed ID: 34727172
[TBL] [Abstract] [Full Text] [Related]
7. Crizotinib: aseptic abscesses in multiple organs during treatment of eml4-ALK-positive NSCLC.
Weber D; Decker M; Schuster M; Folz S; Stürmer CJ; Lutz MP
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3769-3771. PubMed ID: 34373943
[TBL] [Abstract] [Full Text] [Related]
8. Coexistence of a secondary STRN-ALK, eml4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract] [Full Text] [Related]
9. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
[TBL] [Abstract] [Full Text] [Related]
10. Successful Alectinib Treatment for Carcinoma of Unknown Primary with
Sugiyama K; Izumika A; Iwakoshi A; Nishibori R; Sato M; Shiraishi K; Hattori H; Nishimura R; Kitagawa C
Curr Oncol; 2021 May; 28(3):1938-1945. PubMed ID: 34064158
[TBL] [Abstract] [Full Text] [Related]
11. The Prevalence of the eml4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma.
Heriyanto DS; Trisnawati I; Kumara EG; Laiman V; Yuliani FS; Sumpono ASB; Cempaka R; Marcellus ; Budiono E
Pulm Med; 2020; 2020():3578748. PubMed ID: 33425389
[TBL] [Abstract] [Full Text] [Related]
12. Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.
Yu R; Bai H; Gao B; Li T; He X; Zhang P; Wang J
Thorac Cancer; 2021 Jan; 12(1):128-132. PubMed ID: 33225619
[TBL] [Abstract] [Full Text] [Related]
13. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and eml4-ALK rearrangement.
Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
[TBL] [Abstract] [Full Text] [Related]
14. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
[TBL] [Abstract] [Full Text] [Related]
15. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract] [Full Text] [Related]
16. Crizotinib.
Heigener DF; Reck M
Recent Results Cancer Res; 2018; 211():57-65. PubMed ID: 30069759
[TBL] [Abstract] [Full Text] [Related]
17. Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.
Madabhavi I; Patel A; Anand A; Panchal H; Parikh S
Clin Respir J; 2018 Feb; 12(2):806-810. PubMed ID: 27606884
[TBL] [Abstract] [Full Text] [Related]
18. Metastatic eml4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report.
Liang W; He Q; Chen Y; Chuai S; Yin W; Wang W; Peng G; Zhou C; He J
BMC Cancer; 2016 Feb; 16():62. PubMed ID: 26850068
[TBL] [Abstract] [Full Text] [Related]
19. Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors.
Michellys PY; Chen B; Jiang T; Jin Y; Lu W; Marsilje TH; Pei W; Uno T; Zhu X; Wu B; Nguyen TN; Bursulaya B; Lee C; Li N; Kim S; Tuntland T; Liu B; Sun F; Steffy A; Hood T
Bioorg Med Chem Lett; 2016 Feb; 26(3):1090-1096. PubMed ID: 26750252
[TBL] [Abstract] [Full Text] [Related]
20. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and liver Damage in a Patient with eml4-ALK Fusion Gene-positive Lung Adenocarcinoma.
Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
[TBL] [Abstract] [Full Text] [Related]
[Next]
